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1376 LETTERS TO THE EDITORhuman patients with allergic asthma following endobronchial
allergen challenge,E7 and genetic linkage studies showing an
association between functional SNPs in the S1P receptor-1 and
asthma.E8 Thus, whether increased expression of ORMDL3 in
hORMDL3zp32Cre mice increases AHR in the absence of airway
inflammation through reductions in sphingolipid levels is
supported by some,6 but not all, studies of sphingolipids.7,8,E6,E7
Interestingly, in Sptlc21/2 mice, the reduced synthesis of
sphinganine and ceramide was associated with increases in
AHR in the absence of inflammation,6 a phenotype we
have observed in hORMDL3zp32Cre mice.4 However, there are
differences in the profile of sphingolipids reduced in
hORMDL3zp32Cre mice4 (sphinganine, sphingosine, S1P,
ceramide in serum; sphinganine in lung) compared with
Sptlc21/2 mice (sphinganine, ceramide in lung). In addition,
hORMDL3zp32Cre mice4 develop spontaneous airway
remodeling and mucus expression not observed in Sptlc21/2
mice, suggesting that pathways to remodeling and mucus are
independent of the ability of ORMDL3 to inhibit SPT and
sphingolipid synthesis.
Studies have also examined the role of ceramide in mouse
asthma models and demonstrated that allergen challenge
increased lung levels of ceramide in WT mice,E3 whereas
pretreatment with pharmacologic inhibitors of ceramide reduced
AHR, lung eosinophils, and TH2 cytokines.
E3 These studies
suggest that the reductions in serum ceramide levels we have
noted in hORMDL3zp32Cre mice should be associated with
reduced AHR, rather than the increased AHR we have noted in
hORMDL3zp32Cre mice. Thus, the reduced serum ceramide levels
in ORMDL3TGmice, as well as the reduced lung ceramide levels
in Sptlc21/2 mice, do not adequately explain the AHR changes
we have noted in these mice.
In summary, in this study we have demonstrated that
hORMDL3zp32Cre mice had significantly reduced serum levels of
the pathway of sphingolipids regulated by SPT (sphinganine, cer-
amide, sphingosine, and S1P), as well as reduced lung levels of
sphinganine. In addition, we demonstrate that administration of
S1P to naive hORMDL3zp32Cre mice further increases their AHR
associated with increased levels of peribronchial macrophages.
These in vivo studies extend previous in vitro observations that
ORMDL3 inhibits the generation of sphingolipids including cer-
amide and S1P.3 Previous studies have also demonstrated that
increased ORMDL3 activates the ATF6a pathway of the endo-
plasmic reticulum unfolded protein response and that this regulates
levels of SERC2b, which can contribute to AHR.4,9 In addition,
ORMDL3 regulates levels of remodeling genes (TGF-b1,
ADAM8) as well as CC and CXC chemokines implicated in
asthma.9 Further studies are needed to determine which
ORMDL3-regulated pathway (eg, inhibition of sphingolipid syn-
thesis, inhibition of ATF6a and SERCA2b, inhibition of remodel-
ing genes, or other as yet unidentified pathways)E9,E10 could
contribute to increased AHR observed in hORMDL3zp32Cre
mice, and whether in patients with asthma SNPs associated with
increased ORMDL3 expression result in reduced sphingolipid
levels. Such insights are important in understandingwhyORMDL3
on chromosome 17q21 is highly linked to human asthma.
Marina Miller, MD, PhDa
Peter Rosenthal, BSa
Andrew Beppu, BSa
Ruth Gordillo, PhDb
David H. Broide, MB, ChBaFrom athe Department of Medicine, University of California San Diego, La Jolla, Calif;
and bInternal Medicine, Touchstone Diabetes Center, the University of Texas
Southwestern Medical Center, Dallas, Tex. E-mail: dbroide@ucsd.edu.
This study was supported by the National Institutes of Health (grant nos. AI 107779, AI
38425, AI 70535, AI 72115, and AI242236 to D.H.B.).
Disclosure of potential conflict of interest: D. H. Broide has received a grant from the
National Institutes of Health. The rest of the authors declare that they have no relevant
conflicts of interest.
REFERENCES
1. Moffatt MF, Kabesch M, Liang L, Dixon AL, Strachan D, Heath S, et al. Genetic
variants regulating ORMDL3 expression contribute to the risk of childhood
asthma. Nature 2007;448:470-3.
2. Verlaan DJ, Berlivet S, Hunninghake GM, Madore AM, Lariviere M, Moussette S,
et al. Allele-specific chromatin remodeling in the ZPBP2/GSDMB/ORMDL3 locus
associated with the risk of asthma and autoimmune disease. Am J Hum Genet
2009;85:377-93.
3. BreslowDK,Collins SR,BodenmillerB,AebersoldR, SimonsK, ShevchenkoA, et al.
Orm family proteins mediate sphingolipid homeostasis. Nature 2010;463:1048-53.
4. Miller M, Rosenthal P, Beppu A, Mueller JL, Hoffman HM, Tam AB, et al.
ORMDL3 transgenic mice have increased airway remodeling and airway
responsiveness characteristic of asthma. J Immunol 2014;192:3475-87.
5. Warshauer JT, Lopez X, Gordillo R, Hicks J, Holland WL, Anuwe E, et al. Effect
of pioglitazone on plasma ceramides in adults with metabolic syndrome. Diabetes
Metab Res Rev 2015;31:734-44.
6. Worgall TS, Veerappan A, Sung B, Kim BI, Weiner E, Bholah R, et al.
Impaired sphingolipid synthesis in the respiratory tract induces airway hyperreactivity.
Sci Transl Med 2013;5:186ra67, Erratum in: Sci Transl Med 2013;5:192er7.
7. Roviezzo F, D’Agostino B, Brancaleone V, De Gruttola L, Bucci M, De dominicis G,
et al. Systemic administration of sphingosine-1-phosphate increases bronchial hyper-
responsiveness in the mouse. Am J Resp Cell Mol Biol 2010;42:572-7.
8. Price MM, Oskeritzian CA, Falanga YT, Harikumar KB, Allegood JC, Alvarez SE,
et al. A specific sphingosine kinase 1 inhibitor attenuates airway hyperresponsive-
ness and inflammation in a mast cell-dependent murine model of allergic asthma.
J Allergy Clin Immunol 2013;131:501-11.e1.
9. Miller M, Tam AB, Cho JY, Doherty TA, Pham A, Khorram N, et al. ORMDL3 is
an inducible lung epithelial gene regulating metalloproteases, chemokines, OAS,
and ATF6. Proc Natl Acad Sci USA 2012;109:16648-53.
Available online November 5, 2016.
http://dx.doi.org/10.1016/j.jaci.2016.08.053Prenatal phthalate exposure
associates with low regulatory
T-cell numbers and atopic
dermatitis in early childhood:
Results from the LINA
mother-child studyTo the Editor:
Phthalates serve as binders and plasticizers in everyday items,
including cosmetics, household cleaners, food packaging,
personal-care products, toys, and many other consumer products.
Recent publications show that exposure to these chemicals may
contribute to an increased risk of allergy development including
asthma and atopic dermatitis.1,2 An immune modulatory capacity
of these compounds is assumed but not fully elucidated by now.3
Epidemiological studies provide evidence that exposure to phtha-
lates and their metabolites might be more critical in the prenatal
period when the fetal immune system is developing.4 According
to the fact that regulatory T (Treg) cells are key players in the
modulation of immune responses, we asked whether phthalates
may affect the number of these cells leading to the observed
increased risk to develop atopic dermatitis.2 In a recent study,
cord blood 2nd year
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FIG 1. Relationship between maternal urine phthalate metabolite concentrations and the number of Treg
cells. Data represent samples with phthalate and Treg-cell measurements in pregnancy (n 5 542) and with
phthalate measurements in pregnancy and Treg cells in children in cord blood (n 5 448) and at the age of
2 years (n 5 331). Shown are the mean ratios with 95% CI. Mean ratios were adjusted for maternal atopic
dermatitis, maternal smoking and/or ETS exposure at home during pregnancy, maternal education, cat
ownership during pregnancy, and previous births. In addition, data from cord blood were adjusted for sex
and those at the age of 2 years for sex and breast-feeding until 6 months.
TABLE I. Concentrations of phthalate metabolites in maternal
urine (36th gestational week) in regard to the development of
atopic dermatitis (physician diagnosed) in the first 3 years of
children’s life
Phthalate metabolites
Atopic dermatitis 0-3rd year,
median (IQR) (ng/mg)* P
valueyYes (n 5 85)z No (n 5 350)z
MEP 60 (28.3-143.9) 50.5 (23.9-99.4) .155
MiBP 73.3 (53.2-102.9)§ 62.4 (45.7-90.9)§ .036§
MnBP 112.7 (78.8-169.7) 96.9 (66.7-143.9) .057
MBzP 6.9 (3.7-11.7) 6.4 (3.7-10.6) .646
MEHP 7.7 (5.5-11.5) 7.2 (5-10.8) .438
IQR, Interquartile range.
*Concentrations were adjusted for creatinine (in ng per mg of creatinine) to control for
urine dilution.
P values from Mann-Whitney U test.
Cases with maternal phthalate measurements in maternal urine (36th gestational
week).
§Significant values are marked in boldface (P < .05).
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associated with a higher risk to develop an atopic dermatitis
within the first 3 years of life.5 In the present investigation, we
aimed to evaluate whether a high maternal phthalate burden
impacts the number of Treg cells in pregnancy as well as in early
childhood. Associations to children’s atopic dermatitis were
found with the primary metabolites of diethyl, di-n-butyl,
butylbenzyl, or di-2-ethylhexyl phthalate.2 Therefore, in our
study, we measured the concentration of these metabolites
(monoethyl phthalate [MEP], monoisobutyl phthalate [MiBP],
mono-n-butyl phthalate [MnBP], monobenzyl phthalate
[MBzP], mono-(2-ethylhexyl) phthalate [MEHP]) in maternal
urine and assessed the relationship to Treg-cell numbers and the
development of atopic dermatitis as well as to hay fever and
allergic sensitization to food (fx5) and inhalant (sx1) allergens.Datawere gained from our prospective birth cohort study LINA
(Lifestyle and environmental factors and their Influence on
Newborns Allergy risk). For this study, 629 mother-child pairs
(622 mothers, 7 twin pairs) were recruited fromMarch 2006 until
December 2008 in Leipzig, Germany.6 Annually, around the
birthday of the child, follow-up investigations were performed
with questionnaire evaluations for allergic outcomes (atopic
dermatitis, hay fever, asthma) and confounders as well as clinical
visits including blood collection. Early morning urine samples
were collected during the third trimester (gestational age
36 weeks, n 5 610) and analyzed for the primary phthalate
metabolites (MEP, MiBP, MnBP, MBzP, and MEHP) using a
multianalyte procedure as described by Feltens et al.7 Absolute
concentrations of phthalates were calculated on the basis of
calibration curves and normalized to urinary creatinine concen-
trations. The number of Treg cells was determined by FOXP3
methylation-specific real-time PCR in the Treg-cell–specific de-
methylated region in blood samples from pregnancy (34th gesta-
tional week, n5 607), cord blood (n5 448), and from the second
year of children’s life (n 5 331) as described previously.6 This
method enables the identification of cells with stable Treg-cell
phenotype and function.8 Characteristics of the study population,
detailed method description, and median values and interquartile
ranges for all phthalate metabolites and Treg-cell numbers are
given in this article’s Online Repository (Tables E2 and E3 at
www.jacionline.org).
Associations between maternal urine phthalate metabolite
concentrations and the number of Treg cells were calculated
using a linear regression model adjusted for maternal atopic
dermatitis, maternal smoking and/or ETS exposure at home,
maternal education, cat ownership, previous births (presence of
older siblings), and in addition (only for children) for sex and
breast-feeding until 6 months. Out of the analyzed phthalate
metabolites,MEP andMiBPwere associated with lower Treg-cell
numbers in cord blood (adjusted mean ratios [aMR], 0.90, 95%
TABLE II. Relationship between phthalate metabolites (concentration in maternal urine 36th gestational week) exposure and the
development of atopic dermatitis (physician diagnosed) in the first 3 years of children’s life
Phthalate metabolites
Atopic dermatitis 0-3rd year; % (n/N), 19.5% (85/435)*
Crude OR (95% CI) P value Adjusted OR (95% CI)y P value
MEP 1.6 (0.84-3.04) .145 1.45 (0.75-2.83) .268
MiBP 2.15 (1.11-4.14) .022 2.21 (1.1-4.45) .026
MnBP 1.79 (0.95-3.37) .072 1.79 (0.91-3.52) .090
MBzP 1.29 (0.68-2.47) .427 1.28 (0.65-2.52) .470
MEHP 1.47 (0.77-2.79) .242 1.5 (0.76-2.98) .238
*Cases with maternal phthalate measurements in maternal urine (36th gestational week).
Analysis was performed using a logistic regression model with phthalate values categorized into quartiles; odds ratios (ORs) were adjusted for sex, maternal atopic dermatitis,
maternal smoking, and/or ETS exposure at home, siblings, maternal education, cat ownership, and breast-feeding until 6 months.
Significant values are marked in boldface (P < .05).
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respectively) and in children aged 2 years (aMR, 0.85, 95% CI,
0.76-0.96, P 5 .007 and aMR, 0.88, 95% CI, 0.78-0.99,
P 5 .045, respectively) but not in mothers during pregnancy
(aMR, 1.02, 95% CI, 0.94-1.12, P 5 .529 and aMR, 1.07, 95%
CI, 0.98-1.17, P 5 .095, respectively) (Fig 1). We repeated the
analysis on the basis of a subgroup of 208 children with available
data for maternal urine phthalate concentrations and Treg-cell
numbers during pregnancy, as well as Treg-cell measurements
in cord blood and at the age of 2 years and gained similar results.
In addition here, at the age of 2 years, a reduced number of Treg
cells was observed in association with high concentrations of
MnBP during pregnancy (see Fig E1 in this article’s Online
Repository at www.jacionline.org). Although cord blood
Treg-cell numbers are only affected by maternal exposure during
pregnancy, we cannot exclude that phthalate exposure after birth
also contributed to the observed low Treg-cell numbers at the age
of 2 years.
Furthermore, the impact of high phthalate metabolite levels
in pregnancy on the development of atopic dermatitis during
the first 3 years in children’s life was assessed by calculating
odds ratios adjusted for sex, maternal atopic dermatitis,
maternal smoking and/or ETS exposure at home, siblings,
maternal education, cat ownership, and breast-feeding until
6 months. In our study, 19.5% of children developed an atopic
dermatitis within the first 3 years of life. For children who
developed an atopic dermatitis during this time, maternal urine
MiBP concentrations were significantly higher compared with
those in healthy controls (Table I). Furthermore, high maternal
MiBP urine concentrations were associated with a higher risk
for the child to develop an atopic dermatitis until the age of
3 years (adjusted odds ratio, 2.21; 95% CI, 1.1-4.45;
P 5 .026; Table II). These results sustain earlier publications2,9
presenting a relationship between prenatal exposure to phtha-
late metabolites and an increased risk for atopic dermatitis in
early childhood. However, in our study, the metabolite MiBP,
but not MBzP like in the mentioned publications, showed
this association. This apparent discrepancy may reflect the
fact that the studies have been conducted in different coun-
tries/continents, for example, New York (United States),
Taiwan (Asia) versus our study, which is located in Leipzig
(Germany, Europe), where the composition of plastics or con-
sumer products may differ in the distribution of phthalates
compared with that in the other continents. In addition, the
consumer behavior in the different countries and continentsmay also impact the phthalate distribution. At least for MiBP
it is obvious that in our study the concentrations found in
urine are much higher (65.6 mg/g) compared with the
concentrations found in urine in Taiwan (15.2 mg/g), the
United States (8.1 mg/g), or Mexico (8.4 mg/g).7
In addition to the above-described link between MiBP and
atopic dermatitis, we could show that exposure to high concen-
trations of MEP andMnBP during the fetal period was associated
with an increased risk to sensitization to food allergens (fx5) at the
age of 2 years and in trend also at the age of 1 year (see Table E4 in
this article’s Online Repository at www.jacionline.org). We
furthermore could demonstrate that a high number of Treg cells
at birth is protective against sensitization to food allergens at
the age of 1 year and a high number of Treg cells at the age of
2 years was associated with a lower risk for sensitization to
inhalant allergens at this age (see Table E5 in this article’s Online
Repository at www.jacionline.org). As Treg cells are keeping im-
mune responses in balance, lower numbers of these cells may
facilitate the development of allergic diseases, as we could
show earlier for atopic dermatitis.5,6 Interestingly, maternal
Treg-cell numbers in pregnancy were not associated with phtha-
late metabolite concentrations, pointing out that the immature im-
mune system of the fetus and toddler is more vulnerable to these
chemicals. Although we are not able to provide a mechanistic
explanation for the impact of MEP and MiBP on Treg-cell
numbers (which might implicate the differentiation and/or prolif-
eration of these cells), our epidemiological findings may
encourage for the performance of in vitro assays in this direction
in future studies. Taken together, our data suggest that MiBP be-
ing associated with reduced numbers of Treg cells may facilitate
the development of an atopic dermatitis in early childhood.
Because DiBP, the parent compound from which MiBP origi-
nates, is widely used in food packages, adhesives, and cosmetics,
the usage of these products especially during pregnancy should be
avoided.
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http://dx.doi.org/10.1016/j.jaci.2016.09.034Dysregulation of lipidomic profile
and antiviral immunity in response
to hyaluronan in patients with
severe asthmaTo the Editor:
Features of patients with severe asthma include a greater
frequency and severity of hospitalizations caused by pneumonia,
severe influenza, and sinopulmonary infections.1 Viral infections
are frequent triggers of asthma exacerbations.1 Impaired antiviral
responses in asthmatic patients have been noted.2 However, the
mechanisms of this phenomenon are not well understood.
The asthmatic airway wall undergoes many alterations,
including increased and changed deposition of extracellular
matrix. Hyaluronan (HA), a major component of extracellular
matrix, accumulates in the lung and serum of asthmatic patients
and correlates with disease severity.3 Low-molecular-weight
(LMW) forms of HA generated during tissue injury orinflammation have been linked to asthma,3,4 but the mechanisms
of that link are not well understood.
Recently, we described themechanism bywhich LMWHA can
activate cytosolic phospholipase A2a (cPLA2a) and arachidonic
acid (AA) production.5 Previously, we reported increased
expression of cPLA2a in PBMCs of patients with severe asthma.
6
cPLA2a is a rate-limiting enzyme in eicosanoid production,
which is responsible for liberation of AA from cellular
membranes.5 AA is the precursor of leukotrienes, prostaglandins
(PGs), hydroxyeicosatetranoic acids (HETEs), thromboxanes,
lipoxins, and epoxides, many of which are involved in asthma
pathogenesis,7 and they are altered in patients with viral
infections.8
A thorough analysis of LMW HA’s effects on the lipidomic
profile or global gene expression in asthmatic patients has never
been performed, and its possible influence on the disease
progression has not been noted. Therefore we performed a
systemic analysis of LMW HA signaling in PBMCs of patients
with mild-to-moderate and severe asthma by using liquid
chromatography and mass spectrometry combined with
microarray, real-time PCR, and multiplex protein analyses.
Details of methodology are provided in the Methods section in
this article’s Online Repository at www.jacionline.org.
Thirteen asthmatic patients and six control subjects were
enrolled under a National Heart, Lung, and Blood Institute review
board–approved protocol (99-H-0076). Severe asthma was
defined according to European Respiratory Society/American
Thoracic Society guidelines.9 Participants’ demographic and
phenotypic characteristics are presented in Tables E1 and E2 in
this article’s Online Repository at www.jacionline.org.
Of the 151 lipid species profiled, we detected 68 before or after
LMW HA stimulation. At baseline, fewer metabolites were
generated through the COX pathway compared with the
combined lipoxygenase, CYP450, and nonenzymatic pathways
in each group (Fig 1, A, and see Fig E1, A, in this article’s Online
Repository at www.jacionline.org). The relative percentage of all
COX metabolites at baseline was significantly lower in
patients with severe asthma than in control subjects (Fig 1, A,
and see Fig E1, A). However, after LMW HA stimulation,
there was a significant increase in the relative percentage of
COX-generated mediators and a corresponding decrease of
metabolites derived from the other pathways in all groups
(Fig 1, A, and see Fig E1, A).
Analysis of individual lipids revealed that 22 were significantly
upregulated by using LMWHA (Fig E1, B). Although at baseline
several lipid species tended to have lower concentrations in
patients with severe asthma, the increase in 9 metabolites after
LMW HA treatment was significantly more pronounced in those
patients compared with control subjects (Fig 1, B). These
included the COX metabolites thromboxane B2 (TXB2), prosta-
glandin E2, D2 and B2 (PGE2, PGD2, and PGB2) and metabolites
from other pathways, including 15-hydroxyeicosatetraenoic acid
(15-HETE) (through lipoxygenase), 11,12-epoxyeicosatrienoic
acid (11,12-EET), and 14,15-EET (through CYP450), and
non-AA metabolites, such as 13-hydroxyoctadecatrienoic
acid (13-HOTrE(y)) and (16(17)-epoxydocosapentaenoic acid
16(17)-EpDPE). Only in patients with severe asthma did the
levels of most of these metabolites reach the range of activation
of their cognate receptors, although 15-HETE, 14,15-EET, and
16(17)-EpDPE were significantly upregulated also in patients
with mild-to-moderate asthma. Treatment with a specific cPLA2a
METHODS
Study design
Six-hundred twenty-nine mother-child pairs were recruited within the
prospective birth cohort study LINA (Lifestyle and environmental factors and
their Influence on Newborns Allergy risk) from March 2006 until December
2008 in Leipzig, Germany. Blood samples were obtained during pregnancy
(mother, 34th week of gestation), at birth (venous umbilical cord blood), and
annually around the child’s birthday. Early morning urine samples were
obtained from mothers in the 36th week of gestation. Data on confounding
variables, prenatal exposure, lifestyle factors, and children’s disease outcomes
were gained from questionnaires filled in by the parents 4 weeks before birth
and annually thereafter. The present investigation comprises of mothers
having urine sample analyses and measurement of Treg cells in blood samples
as well as childrenwith Treg-cell measurements in cord blood and at the age of
2 years.
Participation was voluntary and informed consent was given by the parents.
This study was approved by the Ethics Committees of the University of
Leipzig (file references 046-2006, 160-2008).
Quantification of Treg cells
Isolation of genomic DNA. Genomic DNA (gDNA) was isolated from
whole blood using the DNA Blood Mini Kit according to manufacturer’s
instructions (Qiagen, Hilden, Germany). Briefly, 200 mL whole blood was
treated with 20 mL Proteinase K (activity, 600 mAU/mL) and incubated with
Buffer AL in a ratio of 1:1 (10 minutes, 568C, 350 rpm). Cell lysis was stopped
by adding 200 mL ethanol. The complete sample volume was transferred onto
a QIAampMini spin column and centrifuged (12,000 rpm). DNA bound to the
QIAamp membrane was washed twice using Buffers AW1 and AW2
(12,000 rpm, 1 minute; 13,000 rpm, 5 minutes). DNA was eluted by adding
Buffer AE and stored at 48C until subsequent analysis, applying the mean of
the 2 reference genes for normalizing.
Bisulfite conversion of gDNA and quantification of Treg cells
by FOXP3 methylation-specific real-time PCR. Bisulfite treatment of
gDNA was conducted using EpiTect 96 Bisulfite Kit (Qiagen, Hilden,
Germany) as described by the manufacturer. Briefly, 1 mg of gDNA, 85 mL
of the Bisulfite Mix, and 35 mL of the DNA Protect Buffer were mixed in a
96-well EpiTect Conversion Plate, and bisulphite conversionwas performed in
a thermal cycler according to manufacturer’s instruction. Converted gDNA
was stored at 2208C until further analysis.
Quantification of demethylation in Treg-cell–specific demethylated region
was performed by real-time PCR by Epiontis (Berlin, Germany; for details,
see data in this article’s Online Repository at www.jacionline.org). As
described previously, the number of Treg cells in blood is presented as
percentage corresponding to the measured amount of Treg-cell–specific
demethylated region demethylation in the FOXP3 gene.E1
Phthalate metabolite measurement in urinary
samples
Phthalate quantification was carried out for 610 early morning maternal
urine samples. In the present study, data for 542 mothers, the subset with
Treg-cell measurements in their blood, are presented. Urine samples were
collected at 36th weeks’ gestation and stored in polypropylene tubes at2808C
until further analysis. Primary phthalate metabolite (MEP, MiBP, MnBP,
MBzP, MEHP) quantification was carried out for all samples using a
multianalyte procedure as described by Feltens et al.E2 Absolute concentra-
tions of phthalate metabolites were calculated on the basis of calibration
curves and normalized to urinary creatinine concentrations as previously de-
scribed.E3 Concentrations are given in ng per mg creatinine.
Allergic outcomes
Information on allergic outcomes was collected using questionnaires self-
administered by the parents. Atopic dermatitis and hay fever were recorded as
physician diagnoses (‘‘Has a doctor diagnosed your child with atopic
dermatitis in the last 12 months?’’; ‘‘Has a doctor diagnosed your child with
hay fever in the last 12 months?’’). The lifetime prevalence within the first
3 years of life was determined by adding the information of having
doctor’s-diagnosed atopic dermatitis or hay fever from each year. The control
group was defined including children having never developed symptoms or
being diagnosed for this disease until the age of 3 years.
Allergic sensitization was assessed by the measurement of specific IgE
against food allergens (fx5) and inhalant allergens (sx1). Samples were
categorized as positive by the cutoff value of more than 0.35 kU/L.
IgE measurement
The concentrations of specific IgE against food (fx5) and inhalant allergens
(sx1) in sera of 1-year-old children were determined by the Phadia CAP
System (Phadia GmbH, Freiburg, Germany). The allergen multipanel fx5
consists of hen’s egg, cow’s milk, wheat, fish, peanut, and soy. Sx1 includes
timothy, rye, mugwort, birch, house dust mite (Dermatophagoides
pteronyssinus), cat, and dog. Samples with a specific IgE concentration of
more than 0.35 kU/L were regarded as positive.
Confounding variables
Information on maternal history of atopy and prenatal exposure was
assessed by detailed questionnaires answered by parents during the third
trimester of pregnancy and annually after delivery. To address maternal atopy
history, we included asthma, hay fever, and atopic dermatitis (‘‘Did you ever
suffer from asthma, allergic rhinitis, atopic dermatitis?’’). Smoking or
exposure to environmental tobacco smoke at home during pregnancy was
recorded with the question ‘‘Did you or anybody else smoke inside your
dwelling during the last twelve months?’’ If yes; occasionally, once per week,
or daily. Maternal education was assessed by asking ‘‘Which is the
highest education level you have?’’ ‘‘low, 9 yr of schooling or less’’
‘‘Hauptschulabschluss’’; ‘‘intermediate, 10 yrs of schooling’’ ‘‘Mittlere
Reife’’; high, 12 yrs of schooling or more ‘‘(Fach-)hochschulreife.’’
Furthermore, the number of present siblings, the presence of pets (including
cats) during pregnancy, and the duration of breast-feeding were recorded.
Statistical analysis
Statistical analyses were performed using Statistica for Windows Version
10.0 (StatSoft Inc [Europe], Hamburg, Germany). The chi-square test for
cross-relationship was performed to ensure the equal distribution of
parameters in the analyzed subgroups and the entire LINA cohort. AllP values
of less than .05 were considered to be significant. Because measured phthalate
metabolite concentrations and Treg-cell numbers were not normally
distributed, a logarithmic transformation was performed. Furthermore, the
data were categorized into quartiles and used in the regression models. To
analyze the relationship between maternal urine phthalate metabolite
concentrations from pregnancy and the number of Treg cells in blood samples
from pregnancy, cord blood, and at children’s age of 2 years, linear regression
models were used. The linear regressionmodels were adjusted for the possible
confounding factors maternal atopic dermatitis, maternal smoking and/or ETS
exposure at home, maternal education, cat ownership, previous births
(presence of older siblings), and also (only for children) for sex and breast-
feeding until 6 months. Data are presented as mean ratios, which are the
back-transformed effects from the regression model of the logarithmically
transformed outcome. Odds ratios were calculated to show the relationship be-
tween prenatal phthalate concentrations inmaternal urine and the development
of atopic dermatitis (physician diagnosed) within the first 3 years of life. The
logistic regression models were adjusted for sex, maternal atopic dermatitis,
maternal smoking and/or ETS exposure at home, presence of older siblings,
maternal education, cat ownership, and breast-feeding until 6 months.
RESULTS
Study population characteristics
Characteristics of the study population are listed in Table E1.
There were no differences in the distribution of considered
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parameters in the analyzed subgroups compared with the entire
LINA cohort. Out of the 622 mothers participating in the study,
542 had urinary samples with phthalate metabolite measurements
as well as Treg-cell measurements in blood. Out of the 470
children with cord blood samples, in 448 the number of Treg cells
was assessed whereas at the age of 2 years, Treg-cell numbers
were measured in 331 out of 339 blood samples. In the analyzed
subgroup of children with prenatal maternal urine phthalate
measurements, 85 (19.5%) developed an atopic dermatitis until
the age of 3 years compared with 92 (18.5%) children from the
entire LINA cohort.
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FIG E1. Relationship between maternal urine phthalate metabolite concentrations and the number of Treg
cells. Results based on the subgroup of children with available data for maternal urine phthalate
concentrations in pregnancy as well as measurements of Treg cells in pregnancy, in children’s cord blood,
and at the age of 2 years (n 5 208). Shown are the mean ratios with 95% CI. Mean ratios were adjusted for
maternal atopic dermatitis, maternal smoking and/or ETS exposure at home during pregnancy, maternal
education, cat ownership during pregnancy, and previous births. In addition, data from cord
blood were adjusted for sex and those at the age of 2 years for sex and breast-feeding until 6 months.
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TABLE E1. Characteristics of the analyzed subgroups and the entire LINA cohort
Parameters
Entire LINA cohort,
n (%), N 5 629
Analyzed subgroups
P
value*
Maternal urine
samples in pregnancy,
n (%), N 5 542y
Cord blood
samples at birth,
n (%), N 5 448z
Blood samples at
children’s age of 2 y,
n (%), N 5 331§
Sex of the child
Male 327 (52) 282 (52) 211 (47.1) 165 (49.8) .885
Female 302 (48.0) 260 (48) 237 (52.9) 166 (50.2)
Maternal history of atopyjj
No 330 (53.1) 280 (51.7) 242 (54) 166 (50.2) .954
Yes 292 (46.9) 262 (48.3) 206 (46) 165 (49.8)
Maternal atopic dermatitis
No 517 (82.2) 443 (81.7) 373 (83.3) 265 (80.1) .947
Yes 111 (17.6) 99 (18.3) 75 (16.7) 66 (19.9)
Maternal education{
Low 24 (3.8) 20 (3.7) 13 (2.9) 6 (1.8) .98
Intermediate 194 (30.8) 165 (30.4) 143 (31.9) 113 (34.1)
High 411 (65.3) 357 (65.9) 292 (65.2) 212 (64)
Breast-feeding until 6 mo
No 139 (23.92) 112 (20.7) 102 (22.8) 77 (23.3) .987
Yes 442 (76.07) 386 (71.2) 311 (69.4) 242 (73.1)
Cat ownership during pregnancy
No 516 (82) 443 (81.7) 364 (81.2) 262 (79.2) .957
Yes 113 (18) 99 (18.2) 84 (18.8) 69 (20.8)
Presence of older siblings
No 420 (66.8) 359 (66.2) 298 (66.5) 218 (65.9) .999
Yes 209 (33.2) 183 (33.8) 150 (33.5) 113 (34.1)
Smoking during pregnancy#
Never 527 (84.7) 465 (85.8) 383 (85.5) 287 (86.7) 1
Occasionally 43 (6.9) 37 (6.8) 23 (5.8) 20 (6)
Once per week 4 (0.7) 4 (0.7) 3 (0.7) 1 (0.3)
Daily 48 (7.7) 36 (6.6) 36 (8) 23 (6.9)
Because of missing data, case number may vary for some variables.
*P value from chi-square test for cross-relationship.
Mothers with phthalate and Treg-cell measurements in pregnancy.
Children with Treg-cell measurements in cord blood.
§Children with Treg-cell measurements at the age of 2 years.
jjHistory of atopy is defined as occurrence of asthma or atopic dermatitis or hay fever.
{Low, 9 years of schooling or less ‘‘Hauptschulabschluss’’; intermediate, 10 years of schooling ‘‘Mittlere Reife’’; high, 12 years of schooling or more ‘‘(Fach-)hochschulreife.’’
#Maternal smoking and/or ETS exposure during pregnancy at home.
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TABLE E2. Maternal urine phthalate metabolite concentrations
(36th gestational week, n 5 542, samples with Treg-cell
measurements)
Phthalate metabolite Median (IQR) (ng/mg)*
MEP 50 (24.8-102.3)
MiBP 66.6 (48.9-99.8)
MnBP 104.9 (69.9-146.8)
MBzP 6.7 (3.8-11.6)
MEHP 7.3 (5.1-11.4)
IQR, Interquartile range.
*Concentrations were adjusted for creatinine (in ng per mg of creatinine) to control for
urine dilution.
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TABLE E3. Treg-cell numbers in samples with phthalate mea-
surements as detected by means of demethylation in the FOXP3
gene
Treg cell Median (IQR) (%)*
Maternal blood (34th gestational week) n 5 542 0.91 (0.56-1.34)
Birth (cord blood) n 5 448 1.18 (0.75-1.71)
Children aged 2 y n 5 331 3.31 (2.49-4.39)
IQR, Interquartile range; TSDR, Treg-cell–specific demethylated region.
*The number of Treg cells is presented as percentage of Treg cells in whole blood
corresponding to the measured amount of TSDR demethylation in the FOXP3 gene.
The detection limit of the FOXP3 TSDR demethylation assay is 0.03%; all values
were above this limit.
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TABLE E4. Relationship between maternal urine phthalate metabolite concentrations (36th gestational week) and allergic outcomes in
the first 3 years of children’s life
Phthalate
metabolites
Allergic outcomes, adjusted OR (95% CI)*
Hay fever Sensitization to food allergens (fx5)y Sensitization to inhalant allergens (sx1)y
0-3rd year,
3.6% (17 of 475)
First year,
15.3% (79 of 515)
Second year,
12.1% (41 of 340)
Third year,
13.8% (40 of 289)
First year,
3.3% (17 of 515)
Second year,
5.3% (18 of 340)
Third year,
12.1% (35 of 289)
MEP 1.05 (0.62-1.76)
P 5 .857
1.23 (0.97-1.57)
P 5 .091
1.49 (1.05-2.13)
P 5 .024
1.23 (0.88-1.72)
P 5 .217
0.95 (0.59-1.53)
P 5 .856
1.14 (0.69-1.85)
P 5 .602
1.06 (0.75-1.51)
P 5 .729
MiBP 1.09 (0.66-1.80)
P 5 .734
0.97 (0.77-1.23)
P 5 .835
1.08 (0.77-1.52)
P 5 .630
0.95 (0.69-1.32)
P 5 .775
1.16 (0.74-1.83)
P 5 .512
1.16 (0.71-1.88)
P 5 .551
1.17 (0.82-1.66)
P 5 .370
MnBP 1.01 (0.61-1.66)
P 5 .972
1.24 (0.98-1.58)
P 5 .065
1.47 (1.05-2.07)
P 5 .025
1.16 (0.84-1.58)
P 5 .357
1.07 (0.68-1.69)
P 5 .771
0.94 (0.59-1.50)
P 5 .803
1.02 (0.73-1.44)
P 5 .879
MBzP 0.98 (0.58-1.67)
P 5 .943
0.83 (0.65-1.05)
P 5 .127
0.95 (0.68-1.33)
P 5 .780
0.92 (0.66-1.27)
P 5 .607
1.03 (0.65-1.62)
P 5 .907
0.97 (0.59-1.58)
P 5 .902
0.94 (0.66-1.33)
P 5 .731
MEHP 1.34 (0.79-2.26)
P 5 .267
0.83 (0.65-1.05)
P 5 .604
1.23 (0.88-1.72)
P 5 .212
1.18 (0.85-1.64)
P 5 .327
1.12 (0.72-1.76)
P 5 .599
1.29 (0.78-2.11)
P 5 .314
1.32 (0.92-1.88)
P 5 .127
Note the reduced case numbers for allergic sensitization because blood samples were not available for all children participating in the follow-up investigation.
*Analysis was performed using a logistic regression model with phthalate values categorized into quartiles; odds ratios (ORs) were adjusted for sex, parental history of atopy,
maternal smoking and/or ETS exposure at home, siblings, maternal education, cat ownership, and breast-feeding until 6 months.
According to the Pharmacia CAP System, concentrations of >0.35 kU/L were regarded as positive.
Significant values are marked in boldface (P < .05).
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TABLE E5. Relationship between Treg-cell numbers and allergic outcomes in the first 3 years of children’s life
Treg cells
Allergic outcomes, adjusted OR (95% CI)*
Hay fever Sensitization to food allergens (fx5)y Sensitization to inhalant allergens (sx1)y
0-3rd year,
3.6% (17 of 475)
First year,
15.3% (79 of 515)
Second year,
12.1% (41 of 340)
Third year,
13.8% (40 of 289)
First year,
3.3% (17 of 515)
Second year,
5.3% (18 of 340)
Third year,
12.1% (35 of 289)
Treg-cell
cord blood
1.59 (0.72-3.54)
P 5 .248
0.72 (0.54-0.96)
P 5 .024
0.97 (0.67-1.41)
P 5 .882
0.83 (0.55-1.21)
P 5 .361
0.97 (0.54-1.73)
P 5 .926
0.71 (0.37-1.39)
P 5 .321
1.02 (0.68-1.53)
P 5 .904
Treg-cell
second year
0.89 (0.51-1.57)
P 5 .695
NA 1.02 (0.75-1.39)
P 5 .869
0.84 (0.61-1.16)
P 5 .292
NA 0.71 (0.43-1.15)
P 5 .169
0.68 (0.46-0.99)
P 5 .046
NA, Not applicable.
*Analysis was performed using a logistic regression model with Treg-cell values categorized into quartiles; odds ratios (ORs) were adjusted for sex, parental history of atopy,
maternal smoking and/or ETS exposure at home, siblings, maternal education, cat ownership, and breast-feeding until 6 months.
According to the Pharmacia CAP System, concentrations of >0.35 kU/L were regarded as positive.
Significant values are marked in boldface (P < .05).
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